Neurocrine Biosciences Inc (NBIX) Cash Flow Statement

A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.

Total Cash From Operating Activities Chart for Neurocrine Biosciences Inc

Neurocrine Biosciences Inc (NBIX) operating cash flow for FY2025 was USD 782.7M, a 31.5% change from FY2024. Neurocrine Biosciences Inc's operating cash flow grew from USD 6.7M in 1996 to USD 782.7M in 2025 (11582.1% over 29 years). Operating cash flow compound annual growth rate: 5-year CAGR of 27.9%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Cash From Operating Activities (US Dollars)

R&D as % of Revenue

Key Stats

Market Cap
$14.79B
Implied Share Price
$145.51
Enterprise Value
$14.42B
Revenue (TTM)
$3.37B
EBITDA
$913.30M
Profit Margin
20.91%
Trailing P/E
21.15
Forward P/E
14.12
Price/Book (MRQ)
3.90
Price/Sales (TTM)
4.38
EV/EBITDA
15.65
EV/Revenue
4.28
Dividend Yield
—
Book Value
$36.35
Free Cash Flow (FY2025)
$748.70M
Free Cash Flow Yield
5.06%

Snapshot as of 6th October 2026 — not point-in-time controlled, may lag the live market by a few days.